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Objective. The aim of the study is to deﬁne predictors of relapse/recurrence after electroconvulsive therapy, ECT, for patients
with major depressive disorder. Methods. A study of all patients (n = 486) treated by means of ECT for major depressive
disorder was performed. The data were derived from a regional quality register in Sweden. Psychiatric hospitalisation or suicide
w a su s e da sam a r k e rf o rr e l a p s e / r e c u r r e n c e .Results. The relapse/recurrence rate within one year after ECT was 34%. Factors
associatedwithincreasedriskofrelapse/recurrenceincludedcomorbidsubstancedependenceandtreatmentwithbenzodiazepines
or antipsychotics during the follow-up period. Conclusions. Within the ﬁrst years after ECT, relapses/recurrences leading to
hospitalisation or suicide are common. Treatment with lithium might be beneﬁcial, while benzodiazepines, antipsychotics, or
continuation ECT does not seem to signiﬁcantly reduce the risk of relapse/recurrence.
1.Introduction
Depression is a major public health concern [1]. In severe
depression, more than 70% of the patients experience
repeated relapses/recurrences, chronicity or commit suicide
[2, 3]. Among patients treated as inpatients, the risk for
rehospitalisation in the ﬁrst year exceeds 30% [4, 5].
Electroconvulsive therapy, ECT, is an eﬀective acute
treatment in severe forms of depression, such as psychotic
or catatonic depression. ECT has also been recommended
in less severe forms of depression after pharmacotherapeutic
failure [6]. However, the rate of relapses/recurrences is high.
Thus, a series of treatment strategies during the follow-
up period has been tested to reduce the risk of relapse/
recurrence. One alternative is antidepressants, commonly
used for relapse/recurrence prevention after ECT. Also
diﬀerent augmentation strategies have been suggested. In
a randomised trial, a lithium-antidepressant combination
was found to be more eﬀective than antidepressants alone
in preventing relapses/recurrences after ECT [7]. Contin-
uation ECT is becoming increasingly used to reduce the
relapse/recurrence rate and is supported by a random-
ised trial in which continuation ECT alone and an anti-
depressant-lithium combination resulted in similar relapse/
recurrence rates [8]. Despite these treatments, relapse/
recurrence rates of 40–50% within 6–12 months after ECT
have been reported [7–9].
Some second-generation antipsychotics have also been
demonstrated to be eﬀective in the acute treatment of major
depressive disorder [10, 11], and a few studies suggest eﬀec-
tiveness in relapse prevention of major depressive disorder
[12]. However, more data on the use of antipsychotics for the
prevention of relapses/recurrences after ECT are needed.
In major depression, a greater number of depressive
episodes tend to increase the risk of subsequent relapses/
recurrences [13]. Patients with diseases resistant to med-
ication have an increased risk of relapse/recurrence after
ECT [14]. In parallel, in several studies of patients treated2 Depression Research and Treatment
for depression with medication, remaining symptoms were
correlated to increased risk of relapse/recurrence [13, 15].
Patientswithcomorbidconditionsmayalsorunanincreased
risk of relapse/recurrence [16, 17]. In some studies severe
symptoms were associated with increased risk of relapse/
recurrence [18].
The aim of the present study is to deﬁne predictors of
timetorelapseafterECTformajordepressivedisorder,single
or recurrent, in a consecutive sample of patients from a
deﬁned geographical area in Sweden.
2. Patientsand Methods
2.1. The Regional Quality Register for ECT. In Sweden, all
ECTs are provided in psychiatric hospitals responsible for
the treatment of all patients in a deﬁned geographical area.
All inhabitants are assigned a personal identiﬁcation number
that is used in the hospital charts and in the computer-
ized administrative systems. Therefore, all inhabitants in a
designated area treated with ECT can be identiﬁed. Seven
hospitals in the middle of Sweden collaborate and report
clinical data to a regional quality register for ECT. The data
in this study were derived from the register. Data about
personal registration number, diagnoses, number of ECT
sessions, treatment parameters, clinical global impression-
improvement (CGI-I) [19], Montgomery ˚ Asberg Depres-
sion Rating Scale-Self-assessment (MADRS-S) [20], phar-
macotherapy, and continuation ECT were reported at the
conclusion of each index series of ECT. The psychiatrist in
chargeofeachpatientdeterminedthediagnosis.Experienced
nurses who met the patients during the ECT assessed CGI-I.
T h eo u t c o m e sw e r eg r a d e da sv e r ym u c hi m p r o v e d ,m u c h
improved, minimally improved, or not improved. A nurse
monitoredtheregisterforcompletenessandvisitedeachhos-
pital every three months to check the data registered with the
data in the hospital charts and patient-administrative sys-
tems.
2.2. Subjects. Inclusion criteria for the study were
(1) treatment with ECT in one of the seven hospitals in
the middle of Sweden between January 1, 2008 and
December 31, 2009,
(2) a diagnosis of major depressive disorder, single epis-
ode or recurrent.
Exclusion criteria were
(1) bipolar disorder,
(2) schizoaﬀective disorder,
(3) schizophrenia.
2.3. ECT Treatment. ECT was administered using a bidirec-
tional constant current, brief pulse device. The Mecta Spec-
trum 5000Q device (Mecta Corp, Lake Oswego, Ore) was
used at ﬁve hospitals, and a Thymatron system IV (Somatics,
Inc, Lake Bluﬀ, Ill) was used at two hospitals.
The mean number of ECT sessions was 7.9 ± 3.0. Most
treatments were unilateral, but in 12% at least one of the
treatments in the series was bitemporal. The mean dosage at
the last treatment if unilateral was 0.46±0.10ms, 75±25Hz,
7.5 ± 0.9s, 833 ± 50mA, and 429 ± 177mC. More than 20
secondsofEEG-monitoredeﬀectwassought.ThemeanEEG
seizure duration was 34 ±15s.
Propofol(meandosage104±40mg)orthiopental(mean
dosage 288±98mg) was used as anaesthetic. Succinylcholine
(1mg/kg) was used as muscle relaxant, and glycopyrrolate
(0.2mg) was used as anticholinergic. If no adverse events
occurred, ECT was continued until the patients were as-
ymptomatic or the physician judged that the patient had
b e n e ﬁ t t e da sm u c ha sp o s s i b l e .
For patients receiving continuation ECT, the mean num-
ber of continuation ECT sessions was 12 ±15.
2.4. Follow-Up Data. Follow-up data were reported to the
register during the summer/autumn2010. Allfollow-updata
from a speciﬁc hospital were collected on the same date.
2.5. Outcome. In the present study, time to psychiatric
hospitalisation or death due to suicide was used as a robust
indicator of a relapse/recurrence. Thus, hospitalisation or
suicideswerethemainoutcomemeasures.Thestartingpoint
was the last day of the ﬁrst index ECT series in the period
andtheendpointtheﬁrstdayofhospitalisationinpsychiatric
care or time of suicide.
2.6. Statistics. The cumulative probability of surviving with-
out psychiatric hospitalisation was calculated with Kaplan-
Meier technique. Diﬀerences in time to relapse were tested
usingunivariateCoxregression.Inordertoassesstherelative
importance of diﬀerent factors, a Cox regression analysis was
performed. Time to relapse was the dependent variable, and
independent variables with a trend toward statistical signif-
icance (P<0.10) in the univariate analyses were entered.
The tests performed were two sided, and alpha was set to
0.05. SPSS version 15.0 (SPSS Inc, Chicago, Ill) was used for
the statistical analyses.
2.7. Ethics. The Regional Ethical Vetting Board in Uppsala
approved the study. The patients were informed about the
register and accepted registration.
3. Results
3.1. Participants. During the period, 487 patients were
treated with ECT for depression.
The subjects are described in Table 1. 56.5% were
w o m e n .T h em e a na g ew a s5 5± 18 years. 77.7% had major
depressivedisorder,recurrentepisodes.86.8%wereinvolun-
tary treatment, and 75.4% were treated as inpatients. 29.5%
had a comorbid anxiety disorder, and 10.4% had comorbid
substance dependence. 7.5% had a personality disorder.
Information about hospitalisations and continuation
ECT was available for patients living in the area. Only one
patient was excluded due to lack of follow-up data. 15
patients migrating from the area were censored in the
statistical analysis at the day of migration. Six patients thatDepression Research and Treatment 3
Table 1: Patient characteristics.
All patients N = 486
Sex Men 43.5%
Women 56.5%
Age, years Mean ± SD 55 ±18
Diagnoses Major depression, single episode 22.3%
Major depression, recurrent 77.7%
Severity
Mild/moderate 35.7%
Severe, nonpsychotic 43.9%
Severe, psychotic 20.4%
Type of care
Involuntary care 13.2%
Voluntary care 86.8%
Outpatient care 24.6%
Inpatient care 75.4%
Comorbid axis 1 diagnosis With comorbid anxiety diagnosis 29.5%
With comorbid substance dependence 10.4%
Comorbid axis II diagnosis With personality disorder 7.5%
CGI
Very much improved 29.8%
Much improved 49.6%
Minimally improved 13.8%
Not improved 6.8%
died from somatic diseases were censored at the day of
death. Information about alive/dead status was available for
all patients. The national causes of death registry provided
causes of death data for all deaths.
The median follow-up time was 564 days (range 173–
1128 days).
3.2. Psychiatric Hospitalisation during Follow-Up. Out of
486 patients, 185 (38.1%) were hospitalised for psychiatric
reasons. The cumulative proportions of the total sample of
patients with relapses/recurrences during six months, one
year, and two years were 25%, 34%, and 44%, respectively.
The cumulative proportions of inpatients with relapses/
recurrenceswere29%,39%,and51%duringsixmonths,one
year,andtwoyears,respectively. Thecumulativeproportions
of outpatients with relapses/recurrences were 12%, 19%, and
25%during six months, oneyear,andtwoyears,respectively.
The main diagnoses at hospitalisation during followup
were depression 90%, borderline personality disorder 3%,
substance dependence 3%, and anxiety disorders 4%. None
of the patients were hospitalised due to mania.
3.3. Mortality. Fifteen patients died during the follow-up
period. Nine patients died from suicide and 6 from somatic
diseases. The cumulative proportion of patients dying from
suicide within one year after ECT was 2%. None of the
patients died from complications of ECT.
3.4. Age, Sex, and Diagnosis. Neither sex nor age signiﬁcantly
inﬂuenced the rate of relapse/recurrence (Table 2).
Patients treated for major depressive disorder, recurrent
episodes had a similar relapse rate as patients treated for the
major depressive disorder, single episode (Table 2).
The severity of the depressive episode was not signiﬁ-
cantly related to the relapse/recurrence rate (Table 2).
A higher proportion of patients with comorbid alcohol
or illicit substance dependence had relapse/recurrence as
compared to patients without such diagnoses (Table 2). The
main diagnosis was major depressive disorder, recurrent
episodes in 21 (77.8%) out of 27 hospitalisations during
followup among patients with substance dependence.
3.5. Symptoms after Index ECT. Symptom control after ECT
as assessed by means of CGI-I did not signiﬁcantly inﬂuence
the rate of relapse/recurrence (Table 2).
3.6. Treatment Factors
3.6.1. Lithium during the Follow-Up Period. Patients receiv-
ing lithium after ECT seemed to have a reduced risk of
relapse as compared to patients without lithium treatment
(HR = 0.51, P = 0.03) (Table 3). However, the patients
were not randomised to lithium treatment. The patients who
received lithium treatment were more often men (58.0%
versus 42.0%, P = 0.03) and they received somewhat more
ECTs during the index series (9.6 ± 4.1v e r s u s7 .8 ± 2.9,
P<0.001).
3.6.2. Antipsychotics during the Follow-Up Period. Nonpsy-
chotic patients treated with antipsychotics had an increased
risk of relapse/recurrence as compared to nonpsychotic4 Depression Research and Treatment
Table 2: Univariate Cox regression analyses of patient risk factors for psychiatric hospitalisation or suicide during followup.
Hazard ratio (HR) 95% Conﬁdence interval (CI) P
Sex Women (n = 275) versus men (n = 211) 1.15 0.86–1.53 0.35
Age (years) 1.00 0.99–1.00 0.28
Diagnoses N = 486
Major depression, recurrent (n = 378)
versus major depression, single episode
(n = 108)
1.26 0.88–1.79 0.21
Severity
Mild/moderate (n = 168) versus severe,
psychotic (n = 98) 1.01 0.67–1.52 0.97
Severe, nonpsychotic (n = 210) versus
severe, psychotic (n = 98) 1.12 0.76–1.66 0.57
Comorbid axis 1
diagnosis
N = 486
With comorbid anxiety disorder
(n = 140) versus without comorbid
anxiety diagnosis (n = 346)
1.12 0.83–1.52 0.47
With substance dependence (n = 50)
versus without substance dependence
(n = 436)
1.90 1.28–2.82 0.001
Comorbid personality
disorder
With personality disorder (n = 37) versus
without known personality disorder
(n = 449)
1.41 0.88–2.26 0.16
CGI
Much improved (n = 229) versus very
much improved (n = 136) 1.23 0.87–1.75 0.25
Minimally improved (n = 63) versus very
much improved (n = 136) 0.99 0.59–1.65 0.96
Not improved (n = 31) versus very much
improved (n = 136) 1.54 0.86–2.75 0.15
Table 3: Univariate Cox regression analyses of the inﬂuence of treatment factors on hospitalisation or suicide during followup.
Hazard ratio (HR) 95% Conﬁdence interval (CI) P
Type of care
Outpatient (n = 119) versus inpatient
(n = 367) 0.43 0.29–0.64 <0.001
Involuntary (n = 63) versus voluntary
(n = 423) 1.01 0.66–1.55 0.95
Patients with
psychotic features
Antipsychotics (n = 54) versus no
Antipsychotics (n = 42) 0.76 0.39–1.49 0.43
Patients without
psychotic features
Antipsychotics (n = 81) versus no
Antipsychotics (n = 293) 1.99 1.41–2.82 <0.001
Lithium treatment
during followup
Lithium (n = 50) versus no Lithium
(n = 429) 0.51 0.29–0.92 0.03
Benzodiazepines
during followup
Benzodiazepines (n = 99) versus no
Benzodiazepines (n = 380) 1.43 1.03–1.99 0.03
Continuation ECT
during followup
Continuation ECT (n = 59) versus no
Continuation ECT (n = 427) 0.83 0.53–1.30 0.42
patients treated without antipsychotics (HR =1.99, P<
0.001).
However, the patients were not randomised to treatment
with antipsychotics. The patients who received antipsy-
chotics were more often treated involuntarily (14.8% versus
3.5%, P<0.001), and they were less often treated as
outpatients (14.8% versus 32.4%, P = 0.002).
3.6.3. Benzodiazepines during the Follow-Up Period. Patients
treated with benzodiazepines during the follow-up period
had an increased rate of relapse/recurrence as compared
to patients without benzodiazepine treatment (HR = 1.43
P = 0.03). However, the patients were not randomised to
treatmentwithbenzodiazepines.Patientstreatedwithbenzo-
diazepines were more often treated for recurrent depression
(88.9% versus 75%, P = 0.003), less often for psychotic
depression (10.3% versus 23.1%, P = 0.021), and were more
often diagnosed with anxiety disorders (40.4% versus 26.3%,
P = 0.006).
3.6.4. Continuation ECT. 59 (12.1%) of the patients received
continuation ECT during the follow-up period. The meanDepression Research and Treatment 5
Table 4: Multivariate Cox regression analysis of the inﬂuence of comorbid substance dependence, inpatient/outpatient status, lithium
treatment, benzodiazepine treatment, and antipsychotics treatment on the risk for psychiatric hospitalisation or suicide during followup
(n = 479).
At last step Hazard ratio (HR) 95% Conﬁdence interval (CI) P
Outpatient 0.42 0.28–0.64 0.00
Substance dependence 1.88 1.26–2.80 0.00
Benzodiazepines 1.50 1.08–2.10 0.02
Antipsychotics 1.39 1.02–1.88 0.04
Lithium 0.58 0.32–1.02 0.06
Model chi-square = 40.0, df = 5, P<0.001
number of continuation ECT sessions was 12 ± 15. Contin-
uation ECT was not associated with a signiﬁcantly reduced
rate of hospitalisation (HR = 0.83, P = 0.42). However,
the patients were not randomised to continuation ECT.
The patients who received continuation ECT more often
had recurrent episodes (89.8% versus 76.6%, P = 0.02),
they were more often treated as outpatients (49.2% versus
21.1%, P<0.001), they more often had a comorbid anxiety
disorder (40.7% versus 27.9%, P = 0.044), and they received
somewhatmoreECTsduringtheindexseries(9.5±3.4v ersus
7.9 ± 3.0, P<0.001).
3.6.5.OutpatientCare. Patientstreatedasoutpatientsduring
their index ECT had a much decreased risk of hospitalisation
or suicide during followup as compared to patients receiving
their index ECT as inpatients (HR = 0.43, P<0.001).
3.7. Signiﬁcant Factors Predicting Relapse. In a multivariate
Cox regression analysis, the following factors were associated
with increased or decreased risk for relapse/recurrence dur-
ing the follow-up period.
Decreased risk: outpatient treatment during the index ECT
series.
Increased risk: comorbid substance dependence, benzo-
diazepine treatment, and treatment with antipsychotics
(Table 4).
4. Discussion
In this naturalistic setting, the cumulative proportion of
patients with relapse/recurrence during one year after ECT
was 35%. Thus, the risk of relapse/recurrence is high, in line
with other studies where relapse/recurrence rates exceeding
30% have been reported [4, 5, 7–9, 21]. Suicide and hospi-
talisation are robust markers of relapse/recurrence. However,
some patients may relapse into less severe symptomatology
not requiring hospitalisation. Thus, we provide conservative
estimates of the true rate of symptom reoccurrence. If
relapse/recurrence had been based on symptomatic worsen-
ing (not hospitalization and suicide), as in the controlled
trials by Sackeim and others [7–9], the relapse/recurrence
rates would most likely have been higher.
Patients with comorbid substance dependence had an
increased risk of hospitalisation during followup. Some of
those patients were hospitalised for other diagnoses than
depression. It is possible that treatment of the comorbid
diagnosis needs more attention, rather than intensiﬁed treat-
ment for depression. The fact that comorbid conditions
increase the risk of relapse/recurrence is in line with results
from other studies [16, 17].
In major depression, a greater number of depressive
episodes tend to increase the risk of subsequent relapses/
recurrences [13]. However, in the present study, patients
with major depressive disorder, recurrent type did not have
signiﬁcantly higher number of relapses/recurrences than the
patients with major depressive disorder, single episode.
In some studies, severe symptoms have been associated
with an increased risk of relapse/recurrence [18]. However,
such a relationship is not supported from the results of the
present study.
As concerns treatment strategies during the follow-up
period, it is diﬃcult to draw ﬁrm conclusions from natu-
ralistic studies as the patients are not randomised and dif-
ferent factors related to selection might have inﬂuenced the
results. However, it is remarkable that benzodiazepines and
antipsychotics during the follow-up period seem to increase
the risk for relapse/recurrence. As concerns antipsychotics,
there are some results indicating a place for the second-
generation antipsychotics in the acute treatment of mood
disorders [11, 22]. In the present study, nonpsychotic
patients treated with antipsychotics had an increased risk
of relapse. The speciﬁc antipsychotic agents used were not
registered, so the eﬀect of diﬀerent antipsychotics could not
becompared.However,thereislittleinformationsupporting
the long-term use of antipsychotics after ECT in patients
with major depressive disorder. Also, metabolic side eﬀects
with antipsychotics should be considered. Patients treated
with benzodiazepines were at increased risk for relapse.
Long-term treatment with benzodiazepines is not supported
by existing guidelines. In addition, there is data suggesting
that benzodiazepines may have a depression-inducing eﬀect
and the risk for iatrogenic substance dependence should be
considered [23].
The present study gives some support to earlier ﬁndings
indicating that lithium might prevent relapse/recurrence
after ECT [7]. However, the patients were not randomised
to lithium treatment. The proportion of patients receiving6 Depression Research and Treatment
lithiumdiﬀeredmarkedlybetweenthesites.Thus,itseemsas
if diﬀerent treatment traditions in the hospitals account for
most of the variation. Possible confounders to the preventive
eﬀect of lithium are a lower proportion of patients with
benzodiazepine treatment and a higher proportion of men.
Although these factors may contribute to the interaction, it
is unlikely that the factors account for most of the eﬀect.
Also, in the multivariate Cox regression model, there was a
tendency towards an eﬀect of lithium for prevention of re-
lapse/recurrence. Thus, the results indicate that more ran-
domised controlled trials are needed to demonstrate if
lithium is an alternative to prevent relapses/recurrences after
ECT.
5. Conclusions
Our results demonstrate that relapses/recurrences resulting
in psychiatric hospitalisation or suicide are common after
ECTandshouldbeamajorconcerneveninremittedpatients
and patients treated for their ﬁrst episode of depression.
A one-year suicide risk of 2% is reported. The high
risk of relapse/recurrence motivates intensive followup and
treatment.Patientswithsubstancedependencehadincreased
risks of relapse after ECT. Treatments with antipsychotics,
benzodiazepines, and continuation ECT were not associated
with signiﬁcant reductions in the risk for relapse/recurrence.
Although the patients were not randomised to these treat-
ments, the lack of eﬀect indicates that better treatment
strategies are needed. Lithium treatment seemed to be asso-
ciated with a reduced risk of relapse. Thus, lithium needs to
be further evaluated in post-ECT relapse prophylaxis of
recurrent major depression.
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